Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Polymorphisms Affecting Gene Transcription and Mrna Processing in Pharmacogenetic Candidate Genes: Detection Through Allelic Expression Imbalance in Human Target Tissues

Abstract 076: the Blood Pressure-associated Non-coding Single Nucleotide Polymorphism Rs28451064 Influences Gene Expression in Human Endothelial Cells

Comparative and Functional Genomic Resource for Mechanistic Studies of Human Blood Pressure–Associated Single Nucleotide Polymorphisms

Next-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brain

Abstract 040: Comparative Genomic Analysis and Functional Insights for Blood Pressure-Associated Single Nucleotide Polymorphisms

Blood Pressure-Associated Non-Coding Single Nucleotide Polymorphism Rs217727 Modulates Gene Expression in Human Endothelial Cells

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Prioritizing Single-Nucleotide Variations That Potentially Regulate Alternative Splicing.

RNA variant assessment using transactivation and transdifferentiation

Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes

Statistical and Functional Studies Identify Epistasis of Cardiovascular Risk Genomic Variants From Genome-Wide Association Studies

Functional Evaluation of Genetic and Environmental Regulators of P450 Mrna Levels.

Genetic variation in human drug-related genes

Quantifying genetic regulatory variation in human populations improves transcriptome analysis in rare disease patients

Coronary artery disease risk factors affected by RNA modification-related genetic variants

A Method for Predicting Allelic Variants of Single Nucleotide Polymorphisms

Non-linear interactions between candidate genes of myocardial infarction revealed in mRNA expression profiles

Genome Wide Analyses Uncover Allele-Specific RNA Editing in Human and Mouse

Genetic variants associated with cell-type-specific intra-individual gene expression variability reveal new mechanisms of genome regulation

Allelic Expression of Deleterious Protein-Coding Variants Across Human Tissues

Comprehensive Cis-Regulation Analysis of Genetic Variants in Human Lymphoblastoid Cell Lines